



**UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE**  
**"CAROL DAVILA" din BUCUREȘTI**



**Anexa 2a**

**VERIFICARE ÎNDEPLINIRE STANDARDE MINIMALE**

DA

NU

Director CSUD.....

**FIȘA DE VERIFICARE**

**a îndeplinirii standardelor minimale în vederea obținerii atestatului de abilitare**

**în cadrul I.O.S.U.D. Universitatea de Medicină și Farmacie "Carol Davila" București**

**Domeniile de doctorat: Medicină, Farmacie**

**I. Date despre candidat**

**Gradul didactic/de cercetare:**

**Nume: OPREA**

**Prenume: ANCA CRISTIANA**

**1. Doctor în științe**

DA

NU

Titlul tezei de doctorat: **Aspecte clinico-evolutive la copiii cu infecție HIV/SIDA transmisă pe cale orizontală**

Ordinul de confirmare: **Ordinul nr. 5237 eliberat de Ministerul Educației și Cercetării 05.11.2004.**

**II. Date numerice privind îndeplinirea standardelor minimale naționale, conform anexelor nr. 20 și 23 ale Ordinului Ministrului Educației Naționale și Cercetării Științifice nr. 6129/20.12.2016**

**1. Articole publicate în reviste cotate ISI în calitate de autor principal**

Criteriul	Standard minim	Realizat
Număr articole publicate în reviste cotate ISI în calitate de autor principal	10	12



**Criteriu îndeplinit:**

DA       NU

**Lista articolelor ISI publicate în calitate de autor principal: autori, titlu articol, revistă, an, volum, pagini, factor de impact**

1. **Oprea C, Ceausu E, Ruță S, Ongoing outbreak of multiple blood-borne infections in injecting drug users in Romania - *Public Health*, Volume 127, Issue 11, 2013, ISSN: 0033-3506, 1048-1050, IF: 2.125**
2. **Ianache I, Calistru P, Tardei G, Ruță S, Oprea C "Late presentation in HIV-infected injecting drug users - a huge challenge for the Romanian health-care system", *Rom J Leg Med* [24] 122-127 [2016], ISSN 1221-8618 (print), IF: 0.15**
3. **Oprea C, Ianache I, Ionescu P, Ceausu E, Calistru P "Malignancies in HIV-infected patients – incidence and predictors of survival in a Romanian health care facility" *Rom. J Leg Med*, 2017, ISSN: 1221-8618, online 1844-8585, p 227-233, IF: 0.15**
4. **Oprea C, Ianache I, Calistru P, Nica, M, Ruta S, Smith C, Lipman M Increasing incidence of HIV-associated tuberculosis in Romanian injecting drug users, *HIV Medicine* 2018 Feb 21. doi: 10.1111/hiv.12576, p 316-323, IF: 3.257**
5. **McCombe G, Cullen W, Lambert JS, Avramovic G, Ianache I, Lazar S, Macias J, Vickerman P, Oprea C -Integrating primary and Secondary care to optimise Hepatitis C treatment; Development and Evaluation of a Multidisciplinary Educational "Masterclass"series, *J of Antimicrobial Chemotherapy*, 74(Supplement 5):v24- v30. IF: 5.217**
6. **Oprea C, In the fight against the Covid- 19 pandemic, testimony of a doctor from the front lines, *Journal of Urban Anthropology*,2021, 17, vol IX, iss2ue 1, ISSN 2286-2390, p 173-189, IF: 1.572**
7. **Lakatos B, Kowalska J, Antoniak S, Gokengin D, Begovac J, Vassilienko A, Wasilewski P, Fleischhans L, Jilich D, Matulionyte R, Kase K, Papadopoulos A, Rukhadze N, Harxhi A, Hofman S, Dragovic G, Vasyliiev M, Verhaz A, Yancheva N, Oprea C - Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug–drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19), *HIV Medicine* 2022; 23:693–700, IF:3.094**



8. **Oprea C, Ianache I, Piscu S, Tardei G, Nica M, Ceausu E, Popescu CP, Florescu SA**, First report of monkeypox in a patient living with HIV from Romania, **Travel Medicine and Infectious Diseases** 49 (2022) 102395, **IF:12**
9. **Oprea C, Popa I, Ianache I, Paun A, Vasile S, Tardei G, et al** Monkeypox, severe hepatitis A and syphilis in a HIV returning traveller from Spain to Romania, **Travel Medicine and Infectious Diseases**, 2022, **IF:12**
10. **Oprea C, Ianache I, Vasile S, Costescu C, Tardei G, Nica M, Umlauf A, Achim C**, Brain opportunistic infections and tumors in people living with HIV - still a challenge in efficient antiretroviral therapy era, **Journal of NeuroVirology**, **IF: 3.739**, 2023<https://doi.org/10.1007/s13365-023-01135-1>
11. **Malciolu AM, Costescu C, Popescu C, Florescu S, Oprea C** - Mpox-related ophthalmic disease -A rare case report, **AIDS Res Hum Retroviruses** 2023 Sep 27.[doi: 10.1089/AID.2023.0010](https://doi.org/10.1089/AID.2023.0010), **IF: 1.723**
12. **Oprea C, Quirke S, Ianache I, Bursa D, Antoniak S, Bogdanic N et al**-For the Euroguidelines in Central and Eastern Europe Network group - HIV disease metrics and COVID-19 infection severity and outcomes in people living with HIV in central and eastern Europe, **HIV Medicine**, 2023;1–10, **IF:3.094**
13. **Oprea Cristiana, Costescu Cristiana, Irina Ianache, Gratiela Tardei, Simin Aysel Florescu** - A Severe Case of Mpox Complicated with Penile Necrosis and Keratitis in a Patient Living with HIV, **Travel Medicine and Infectious Diseases**, vol. 55, 2023, **IF:12**

## 2. Articole publicate în reviste cotate ISI în calitate de coautor

Criteriul	Standard minim	Realizat
Număr articole publicate în reviste cotate ISI în calitate de coautor	5	41



**Criteriu îndeplinit:**

DA       NU

**Lista articolelor ISI publicate în calitate de coautor: autori, titlu articol, revistă, an, volum, pagini, factor de impact**

1. Mbisa JL, Hue S, Buckton AJ, Myers RE, Duiculescu D, Ene L, **Oprea C**, Tardei T, Rugina S, Mardarescu M, Pilay D "Phylogenetic and Phylogeographic Patterns of the HIV-1 subtype F1 Parenteral epidemic in Romania, AIDS Res Human Retroviruses 2012, ISSN: 1931-8405, ISSN online 0889-2229, p961-966, IF: 2.246
2. Mussini C, Antinori A, Bhagani S, Branco T, Brostrom M, Dedes N, Berezky T, Girardi E, Gökengin D, Horban A, Lacombe K, Lundgren JD, Mendao L, Mocroft A, **Oprea C**, Porter K, Podlekareva D, Battegay M, d'Arminio Monforte A; European AIDS Clinical Society Standard of Care meeting on HIV and related coinfections: The Rome Statements, HIV Medicine.2015, ISSN: 1468-1293, IF: 3.341. p 445-452 In acest articol sunt **autor principal** în secțiunea "Improving acces to antiretroviral therapy"
3. Dinu S, Târdei G, Ceausu E, Moțoc A, **Oprea C**, Ungureanu E, Ene L, Duiculescu D, Ciofleac DB, Oprîșan G. "Roum Arch Microbiol Immunol. 2015 Jan-Jun; 74 (1-2):18-25 ISSN 1222-3891, IF: 0.31
4. Ceaușu E, Erșcoiu S, Calistru P, Ispas D, Dorobăț O, Homoș M, Bărbulescu C, Cojocaru I, Simion CV, Cristea C, **Oprea C**, Dumitrescu C, Duiculescu D, Marcu I, Mociorniță C, Stoicev T, Zolotușca I, Calomfirescu C, Rusu R, Hodrea R, Geamai S, Păun L., Clinical manifestations in the West Nile virus outbreak., Rom J of Virol, 1997 Jan-Dec;48(1-4):3-11 IF: 3.257
5. Kowalska JD, **Oprea C**, de Witt S, Pozniak A, Gökengin D, Youle M, Lundgren JD, Horban A; ECEE Network Group Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration – a comprehensive meeting report, HIV Medicine, 2016. Online ISSN: 1468-1293, p 370-375, IF: 3.257
6. Sultana C, Oprisan G, Grancea C, Teleman MD, **Oprea C**, Florescu S, Dinu S, Ceausu E, Ruță S Interferon-gamma inducible Protein 10- biomarker for treatment



- outcome in chronic hepatitis C, Romanian Biotechnological letters, 2016, vol 22, IF: 0.396
7. Sultana C, Opreșan G, Teleman MD, Dinu S HepGen 88/2012 Project Team, **Oprea C**, Voiculescu M, Ruță S, Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C - World J Gastroenterol. 2016 Oct 7; 22(37):8406-8413, ISSN 1007-9327, ISSN online 2219-2840, IF: 2.787
  8. Gökengin D, **Oprea C**, Uysal S, Begovac J. The growing HIV epidemic in Central Europe: a neglected issue? J Virus Erad. 2016 Jul 1; 2(3):156-161, ISSN: 2055-66-40, IF: 5.1
  9. Ruță S, Sultana C, **Oprea C**, Vagu C, Ceausu E, Cernescu C., HCV non-B genotypes in injectable drug users from Romania, J Infect Dev Ctries. 2016 May 31;10(5):523-7, ISSN 1972-2680 IF: 1.67
  10. Ryome L, Boesecke C, Gisler V, Manzano C, Rockstroh JD, Puoti M, Furrer H, Miro JM, Gatell JM, Pozniak A, Behrens G, Battegay M, Lundgren JD, EACS Governing board (**Oprea C**), Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV- positive persons, HIV Medicine, 2016, 17(2), 83-8, Online ISSN: 1468-1293, IF: 3.257
  11. Temereanca A, **Oprea C**, Wertheim J et al "HIV transmission clusters among injecting drug users in Romania" Romanian Biotechnological Letters, Vol. 22, No. 1, 2017, ISSN; 1224-5984, ISSN; 1224-5984, p 12307- 12315, IF: 0.412
  12. De Wit S, Battegay M, D'Arminio Monforte A, Lundgren JD, **Oprea C**, Antinori A, Bhagani S, Fätkenheuer G, Friis-Moller N, Furrer H, Mussini C; European AIDS Clinical Society Second Standard of Care Meeting, Brussels 16-17 November 2016: a summary, HIV Medicine, 2017, Oct 2017, doi: 10.1111/hiv.12559 IF: 3.257
  13. Swan D, Cullen W, Macias J, **Oprea C**, Story A, Surey J, Vickerman P, Lambert JS Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocol. Expert Rev Gastroenterol Hepatol. 2018 Mar;12(3):303-314. doi:10.1080/17474124.2018.1424541. IF: 2.991



14. Gokengin D, **Oprea C**, Begovac J et al. HIV care in Central and Eastern Europe: How close are we to the target? *Int J Infect Dis.* 2018 May; 70:121-130. doi: 10.1016/j.ijid.2018.03.007. Epub 2018 Mar 14, IF: 3.53
15. Balayan T, **Oprea C**, Yurin O et al People who inject drugs remain hard- to- reach population across all HIV continuum stages in Central, Eastern and South Eastern Europe- data from Euro-guidelines in Central and Eastern Europe Network, *Infectious Diseases* 2019, Epub 21 Feb 2019, IF: 3.041
16. Laut K, Kirk O, Rockstroh J, Phillips A, Ledergerber B, Gatell J, Gazzard B, Horban A, Karpov I, Losso M, d'Arminio Monforte A, Pedersen C, Ristola M, Reiss P, Scherrer AU, de Wit S, Matulionyte R, **Oprea C**, Kowalska JD, Begovac J, Miró JM, Guaraldi G, Paredes R, Raben D, Podlekareva D, Peters L, Lundgren JD, Mocroft A. The EuroSIDA study; 25 years of scientific achievements, *HIV Medicine* 2019 Oct 24. doi: 10.1111/hiv.12810, p 71-83, IF: 3.98
17. Negru A, Tiliscan C, Tudor AM, **Oprea C**, Ianache I, Lazar M, Arama V, Arama SS Identifying the risk factors for low bone mineral density disorders in HIV positive patients undergoing antiretroviral therapy from the Romanian cohort, *FARMACIA*, 2019, Vol. 67, 3, p 383-391, IF:1.607
18. Manasturean C, **Oprea C**, Otelea D, Georgescu AM, Diagnostic Difficulties in a Severely Ill HIV Patient with Multiple Superinfections - A Case Report, *The Journal of Critical Care Medicine* 2019 Nov 27;5(4):136-139, IF: 1.1
19. Avramovic G, **Oprea C**, Surey J, Story A, Macias J, Cullen W, Ianache I, Lazar S, Lambert JS, Hepcare Europe-A service innovation project, Hepcheck: characteristics of the patient population with active infection as measured by RNA PCR, *J of Antimicrobial Chemotherapy Int J Infect Dis.* 2019 Nov 27;91:246-251. IF: 5.217
20. Nic An Riogh E, Swan D, McCombe G, O'Connor E, Avramovic G, Macías J, **Oprea C** et al Integrating hepatitis C care for at-risk groups (HepLink): baseline data from a multicentre feasibility study in primary and community care. *J Antimicrob Chemother.* 2019 Nov 1;74(Supplement\_5): v31-v38. IF: 5.217





21. Barror S, Avramovic G, **Oprea C**, Surey J, Story A, Macías J, et al HepCare Europe: a service innovation project. HepCheck: enhancing HCV identification and linkage to care for vulnerable populations through intensified outreach screening. A prospective multisite feasibility study. *J Antimicrob Chemother.* 2019 Nov 1;74(Supplement\_5): v 39-v46. IF: 5.217
22. Ryom L, Cotter A, De Miguel R, Béguelin C, Podlekareva D, Arribas JR et al - EACS Governing Board (**Oprea C**) 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0, *HIV Medicine* 2020 Nov;21(10):617-624 doi: 10.1111/hiv.12878, IF: 3.556
23. Avramovic G, Reilly M, Cullen W, Macías J, McCombe G, McHugh T, **Oprea C**, Story A, Surey J, Sabin C, Bivegete S, Vickerman P, Walker J, Ward Z, Lambert JS -HEPCARE EUROPE- A case study of a service innovation project aiming at improving the elimination of HCV in vulnerable populations in four European cities, *Int J Infect Dis* 2020 Dec;101:374-379. doi: 10.1016/j.ijid.2020.09.1445. IF: 8.4
24. Mocroft A, Ryom L, **Oprea C** et al, EUROSIDA study group- Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV- positive persons, *AIDS* 2020, Aug 1, 34(10):1485-1495, IF: 4.17
25. Mocroft A, Lundgren J, Rockstroh J, Aho I, Wandeler G, Aho I, Nielsen L, Viard JP, Lacombe K, Guaraldi G, Laguno M, Edwards S, Fatkenheuer G, Llibre J, Elinv F, Flamholz L, Gisinger M, Paduta D, Khromova I, Jilich D, **Oprea C**, Lars P, Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons, EUROSIDA study, *Open Forum Infect Dis* 2020 Oct 7;7(12) IF: 4.2
26. Balayan T, Begovac J, Skrzat-Klapaczyńska A, Aho I, Alexiev I, Bukovinova P, Salemovic D, Gokengin D, Harxhi A, Holban T, Jevtovic D, Kase K, Lakatos B, Latysheva I, Matulionyte R, **Oprea C**, Papadopoulos A, Rukhadze N, Sedlacek D, Tomazic J, Vassilenko A, Vasylyev M, Verhaz A, Yancheva N, Yurin O, Horban A, Kowalska JD; ECEE Network Group. - Where are we with pre-exposure prophylaxis use in Central and Eastern Europe? Data from the Euroguidelines in



- Central and Eastern Europe (ECEE) Network Group, HIV Medicine 2021 Jan;22(1):67-72. doi: 10.1111/hiv.12960, IF: 2.42
27. Glaspy S, Avramovic A, McHugh T, **Oprea C**, Surey J, Ianache I, Macías J, Story A, Cullen W, Lambert J S - Exploring and understanding HCV patient journeys- HEPCARE Europe project, BMC Infect Dis 2021 Mar 5;21(1):239. doi: 10.1186/s12879-021-05928-9, IF: 2.864
28. Loveleen Bansi – Matharu, Andrew Philips, **Cristiana Oprea** et al., Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium, Lancet HIV, September 20, 202, IF: 16.07
29. Jilich D, Skrzat-Klapaczyńska A, Fleischhans L, Bursa D, Antoniak S, Balayan T, Begovac J, Cicic A, Dragovic G, Gokengin D, Harxhi A, Kase K, **Oprea C** et al National strategies for vaccination against COVID-19 in people living with HIV in Central and Eastern European region, HIV Medicine 2021, p 546-552, IF: 3.18
30. RESPOND Study group -**Oprea C** Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents, AIDS 2021, 35:869-882, IF: 4.632
31. Kowalska JD, Bienkowski C, Fleischhans L, Antoniak S, Skrzat-Klapaczynska A, Suchacz M, Bogdanic N, Gokengin D, **Oprea C**, Karpov I, Kase K, Matulionyte R, Papadopoulos A, Rukhadze N, Harxhi A, Jilich D, Lakatos B, Sedlacek D, Dragovic G, Vasylyev M, Verhaz A, Yancheva N, Begovac J and Horban A, The Presence of Either Typical or Atypical Radiological Changes Predicts Poor COVID-19 Outcomes in HIV-Positive Patients from a Multinational Observational Study: Data from Euroguidelines in Central and Eastern Europe Network Group, Viruses 2022, 14, 972, p 1-12, IF: 4.7
32. Sultana C, Casian M, **Oprea C**, Ianache I, Grancea C, Chiriac D, Ruta S Hepatitis B Virus Genotypes and Antiviral Resistance Mutations in Romanian HIV – HBV Co-infected patients, Medicina 2022, IF: 2.95
33. Skrzat- Klapaczynska A, Kowalska JD, Afonina L, Antonyak S, Balayan T, Begovac J, Bursa D, Dragovic G, Gokengin D, HARxhi A, Jilich D, Kase K, Lakatos B, Mardarescu M, Matulionyte R, **Oprea C**, Panteleev A, Papadopoulos A, Sojak





- L, Tomazic J, Vassilienko A, Vasylyev V, Verhaz A, Yancheva N, Yurin O, Horban A. The Management of HIV care services in Central and Eastern Europe: Data from the Euroguidelines in Central and Eastern EuropeNetwork Group, Int.J. Environ. Res. Public Health 2022,19, 7595, IF: 4.61
34. Ulfhammer G, Eden A, Antinori A, Brew BJ, Calgagno A, Cinque P, De Zan V, Hagberg L, Lin A, Nilsson S, **Oprea C**, Pinnetti C, Spudich S, Trunfio M, Wiston A, Price RW, Gisslen M, Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 Infection: A Cross- Sectional Multicenter Study, Clinical Infectious Diseases 2022, p 493-502, IF:11.8
35. Papadopoulos A, Konstantinos Th, Konstantinos P, Antonyak S, Begovac S, Dragovic G, Gokengin D, Aimla K, Krasniqi V, Lakatos B, Mardarescu M, Matulionyte R, Mulabdic V, **Oprea C**, Panteleev A, Sedlacek D, Sojak L, Skrzat-Klapaczynska A, Vassilienko A, Yancheva N, Yurin O, Horban A, Kowalska JD. HIV treatment strategies across Central, Eastern and Southeastern Europe: New times, old problems, HIV Medicine 2022, p 1-9, IF:3.094
36. Gokengin D, Bursa D, Skrzat- Klapaczynska A, Alexiev I, Arsikj E, Balayan T, Begovac I, Cacic A, Dragovic G, Harxhi A, Aimla K, Lakatos B, Matulionyte R, Mulabdic V, **Oprea C**, Papadopoulos A, Rukhadze N, Sedlacek D, Sojak L, Tomazic J, Vassilienko A, Vasylijev M, Verhaz A, Yancheva N, Yurin O, Kowalska J - PrEP Scale-up and PEP in Central and Eastern Europe; Changes in time and Challenges we face with no expected HIV vaccine in the near future, Vaccines 2023, 11, 122, p 1-12, IF:7.8
37. Mocroft A, Geressu A, Beguelin C, Libre JM, Lazarus JV, Tomazic J, Smidt J, Parczewski M, Brannstrom J, Sedlacek D, Degen O, Van der Valk M, Paduta D, Flamholz L, Schmid P, Orkin C, Nielsen LN, Hoffmann C, Beniowski M, **Oprea C**, Begovac J, Peters L, The role of HIV/ hepatitis B/ hepatitis C virus RNA+ triple infection in end- stage liver disease and all- cause mortality in Europe. AIDS 2023, 37:91-103, IF: 4.632
38. Bajdechi M, Gurghean A, Bataila V, Scafa- Udriste A, Bajdechi G E, Radoi R, **Oprea C**, Chioncel V, Mateescu A, Zekra L, Cernat R, Dumitru IM, Rugina S



- Particular aspects related to CD4 level in a group of HIV- infected patients and associated acute coronary syndrome, *Diagnostics*, 2023, 13(16), 2682, IF: 3.992
39. Bajdechi M, Gurghean A, Bataila V, Scafa- Udriste A, Radoi R, **Oprea C**, Marinescu A, Stefan I, Cernat R, Chioncel V, Nicula A, Anastasiou A, Bajdechi GE, Savulescu- Fiedler I, Dumitru IM, Rugina S Cardiovascular risk factors, angiographical features and short-term prognosis of acute coronary syndrome in people living with HIV; results from a retrospective observational multicentric Romanian study, *Diagnostics*, 2023, 13, 1526, IF: 3.992
40. Kerstin Aimla, Justyna Dominika Kowalska, Raimonda Matulionyte, Velida Mulabdic, Anna Vassilenko, Natalie Bolokadze, David Jilich, Sergii Antoniak, **Cristiana Oprea**, Tatevik Balayan et al on behalf of the Euroguidelines in Central and Eastern Europe Network Group - Vaccination against HBV and HAV as Mode of Hepatitis Prevention among People Living with HIV- Data from ECEE Network Group, *Vaccines* 2023, 11, 980, p1-9, IF:7.8
41. Ambrosioni J, Laura Levi, Jasmini Alagaratnam, Kathrin Van Bremen, Mastrangelo A, Hylke Waalewijn, Molin JM, Guaraldi G, Winston A, Boesecke C, Paola Cinque, Bamford A, Alexandra Calmy, Catia Marzolini, Martínez E, **Cristiana Oprea**, Welch S, Anna Koval, Mandao L, Rockstroh J, The EACS Governing Board - Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023, *HIV Medicine*, 2023;1-11, IF:3.094

**3. Factorul cumulat de impact pentru articolele publicate ca autor principal în reviste cotate ISI (FCIAP)**

Criteriul	Standard minim	Realizat
(ISI) Factor cumulat de impact autor principal	10	55.58

**Criteriu îndeplinit:**

DA       NU



UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE  
"CAROL DAVILA" din BUCUREȘTI



4. Indexul Hirsch

Criteriul	Standard minim	Realizat
Index Hirsch	6	10

Criteriu îndeplinit:

DA       NU

Confirm prin prezenta că datele menționate mai sus sunt reale și se referă la propria mea activitate profesională și științifică

Data

Semnătura candidatului

10.02.2024

Note asupra metodei de calcul:

1. O revistă cotate ISI este o revistă pentru care Thomson Reuters calculează și publică factorul de impact în „Journal Citation Reports”;
2. Autorul sau autorii principali ai unei publicații se consideră a fi oricare dintre următorii:
  - a. Primul autor
  - b. Autorul corespondent
  - c. Alți autori, a căror contribuție este indicată explicit în cadrul publicației a fi egală cu contribuția primului autor sau a autorului corespondent
  - d. Ultimul autor
3. În analiză vor fi incluse articole originale și reviews. În cazul publicațiilor în reviste cu factor de impact mai mare decât 3, pot fi luate în considerare și alte tipuri de publicații în extenso (nu rezumate).
4. Articolele din cadrul standardelor minimale și obligatorii trebuie să fie publicate și indexate, nu în curs de publicare (nu se acceptă adevărurile).
5. Factorul cumulat de impact va fi calculat pentru articolele la care candidatul este autor principal (FCIAP). FCIAP = suma factorilor de impact ai articolelor publicate de autor în calitate de autor principal în reviste cotate ISI; **factorul de impact se calculează la data apariției articolului.**
6. Va fi luat în considerare Indexul Hirsch calculat utilizând ISI Web of Science, Core Collection, Thomson Reuters, pentru întreaga carieră a candidatului („all years”);